Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab plus durvalumab in extensive-stage small-cell lung cancer
NCT06211036Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2024
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 29
01
Overview
A Phase 3 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Jun 2024; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06211036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211036.